Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Matter-Walstra, Klazien; Klingbiel, Dirk; Szucs, Thomas D.; Paulweber, Bernhard; Schwenkglenks, Matthias

doi:10.1007/s40273-014-0151-0

Cited by 31 publications

(26 citation statements)

References 22 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The values available to us were based on the UK value set. There is no Swiss-specific value set, but a recent study reported that the UK value set generates lower utilities than the German or French value set [ 65 ]. Because of the small difference, we have no reason to assume that this had a substantial impact on our results, at least not in the sense of favouring sofosbuvir.…”

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

et al. 2015

Self Cite

View full text Add to dashboard Cite

In clinical trials, sofosbuvir showed high antiviral activity in patients infected with hepatitis C virus (HCV) across all genotypes. We aimed to determine the cost-effectiveness of sofosbuvir-based treatment compared to current standard treatment in mono-infected patients with chronic hepatitis C (CHC) genotypes 1–4 in Switzerland. Cost-effectiveness was modelled from the perspective of the Swiss health care system using a lifetime Markov model. Incremental cost-effectiveness ratios (ICERs) used an endpoint of cost per quality-adjusted life year (QALY) gained. Treatment characteristics, quality of life, and transition probabilities were obtained from published literature. Country-specific model inputs such as patient characteristics, mortality and costs were obtained from Swiss sources. We performed extensive sensitivity analyses. Costs and effects were discounted at 3% (range: 0–5%) per year. Sofosbuvir-containing treatment in mixed cohorts of cirrhotic and non-cirrhotic patients with CHC genotypes 1–4 showed ICERs between CHF 10,337 and CHF 91,570 per QALY gained. In subgroup analyses, sofosbuvir dominated telaprevir- and boceprevir-containing treatment in treatment-naïve genotype 1 cirrhotic patients. ICERs of sofosbuvir were above CHF 100,000 per QALY in treatment-naïve, interferon eligible, non-cirrhotic patients infected with genotypes 2 or 3. In deterministic and probabilistic sensitivity analyses, results were generally robust. From a Swiss health care system perspective, treatment of mixed cohorts of cirrhotic and non-cirrhotic patients with CHC genotypes 1–4 with sofosbuvir-containing treatment versus standard treatment would be cost-effective if a threshold of CHF 100,000 per QALY was assumed.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, more emphasis should be placed on generating locally-relevant data in the future. [199][200][201][202][203][204].…”

Section: Decision-makers' Guidance On the Approach For Estimating Utimentioning

confidence: 99%

EQ-5D in Central and Eastern Europe: 2000–2015

et al. 2016

View full text Add to dashboard Cite

Increasing use of EQ-5D is observed throughout CEE. The spread of health technology assessment activities in countries seems to be reflected in the number of EQ-5D studies. However, improvement in informed use and methodological quality of reporting is needed. In jurisdictions where no national value set is available, in order to ensure comparability we recommend to apply the most frequently used UK tariff. Regional collaboration between CEE countries should be strengthened.

show abstract

“…The EQ-5D is one of the most feasible tools to assess individuals' QoL, and evaluates their physical, mental and social performance [12]. It has been validated and used in many studies to determine QoL in chronic diseases such as diabetes, chronic lung diseases, stroke and chronic mental illnesses [13][14][15][16][17]. Currently three versions of EQ-5D are available including EQ-5D-3 L, EQ-5D-5 L and EQ-5D-y.…”

Section: Introductionmentioning

confidence: 99%

The quality of life of the patients with diabetes type 2 using EQ-5D-5 L in Birjand

Abedini

Bijari

Miri

et al. 2020

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background: Due to high prevalence of diabetes and its complications, evaluating of the patients' quality of life is critical. EQ-5D-5 L is a valid tool for assessing the quality of life in chronic diseases including diabetes. The present study conducted to illustrate the quality of life for the patients who referred to the Diabetes clinic and determine its relationship with their demographic and clinical characteristics in Birjand in 2017. Methods: In this cross-sectional study, 300 patients with type 2 diabetes were selected through a systematic sampling in 2017. Data were collected using a checklist including patients' demographic, clinical and laboratory information and the EQ-5D-5 L. Data were entered the SPSS (22) software, analyzed by independent sample T-test, ANOVA, Chi-Square and logistic regression tests. Statistical significance was inferred at α = 0.05. Results: Mean age for the participants was 58.1 ± 9.6 years. The mean score for the quality of life based on the EQ-5D-5 L and VAS scale were 0.89 ± 0.13 and 65.22 ± 9.32, respectively. Moderate and severe problems were found in the anxiety/depression dimensions in 12% of the patients, while these numbers for the presence of pain/discomfort and mobility were slightly higher (13.7 and 13.6%, respectively). The mean scores for quality of life and VAS were significantly higher in the men, employed and patients < 50 years age. Conclusion: The quality of life for the type 2 diabetes patients is affected by numerous factors including sex, occupation, duration of the disease and the presence of complications such as neuropathy and nephropathy.

show abstract

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Cited by 31 publications

References 22 publications

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C

EQ-5D in Central and Eastern Europe: 2000–2015

The quality of life of the patients with diabetes type 2 using EQ-5D-5 L in Birjand

Contact Info

Product

Resources

About